News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

“With the $300 million financing from NantCapital combined with the equity raised over the last nine months, we have made the decision to pause the At-the-Market offering and we are well positioned to further accelerate development of our oncology and COVID-19 trials— with the goal of bringing these promising technologies to more people in need globally.”

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing https://www.businesswire.com/news/home/20211220005286/en/

PSS: Nächste Woche startet Phase 3 in Afrika https://mobile.twitter.com/immunitybio/status/1471613689539153925

SEC Form 4: Sachs David C. converted options into 17,242 shares, increasing direct ownership by 65% to 43,700 units https://quantisnow.com/insight/2133072?s=s

Billionaire doctor Patrick Soon-Shiong's mission to place SA at forefront of the Covid fight https://www.news24.com/you/news/local/billionaire-doctor-patrick-soon-shiongs-mission-to-place-sa-at-forefront-of-the-covid-fight-20211126

40th Annual J.P. Morgan Health Care Conference JAN 10 - JAN 13, 2022 https://ir.immunitybio.com/events/event-details/40th-annual-jp-morgan-health-care-conference

ASCO® Gastrointestinal Cancers Symposium JAN 20 - JAN 21, 2022 https://ir.immunitybio.com/events/event-details/ascor-gastrointestinal-cancers-symposium

Video and full transcript of PSS' talk from this morning: https://mobile.twitter.com/gojadas/status/1468313654693175310?s=20

ImmunityBio Strikes Deals in Effort to Speed Development of Covid Vaccine https://labusinessjournal.com/news/2021/dec/06/immunitybio-strikes-deals-effort-speed-development/

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination. https://www.google.com/amp/s/www.news-medical.net/amp/news/20211205/Preclinical-data-shows-enhanced-T-cell-responses-neutralization-of-SARS-CoV-2-variants-with-ImmunityBio-heterologous-vaccination.aspx

"Once clinical trials are completed, the COVID-19 vaccine and other therapies could be available within a year."

"You need to find a vaccine that is durable, long-lasting," he said. "But you also, in real practical terms, need to find a vaccine you can manufacture in billions of doses at scale. And thirdly, you need to find a vaccine you can keep at room temperature. "This checks all those boxes. You can generate trillions of these EDVs and transfer this to under-developed countries, such as in Africa." But EngeneIC's technology has potential for so much more — able to fight other viruses and even the most drug-resistant cancer cells. As Dr Brahmbhatt explained, "This little nano cell can be loaded up with very toxic drugs and it only targets cancer cells — does not touch the normal cells in the body. "Therefore, there are no toxic side effects in our cancer patients. At the same time, it trains the immune system to be able to recognise those cancer cells and it specifically knocks it off."

"The other key positive of this new technology is it's cheaper and easier to make and deliver. "It can be freeze-dried and presented as a powder and you just add water," Dr MacDiarmid said. "And that means you take away all the cold chain. It can be sent out to remote spots, including to our indigenous communities."

"What he's most excited about is EngeneIC's unique COVID-19 vaccine. And here's why: The COVID-19 virus has what's known as spike proteins — raised bumps on its surface. Current vaccines use antibodies to target those spike proteins, but only have a few keys to latch on. Like Velcro, Engeneic's vaccine has many more keys, so sticky and strong it holds on no matter how much the virus mutates. "This is the first, I believe, COVID vaccine that will use this approach," Dr Soon-Shiong said. "And the preliminary data, clinical data and phase one data is incredibly promising." In trials with six healthy patients, the EDV vaccine neutralised 95 per cent of all current COVID-19 variants. But it hasn't yet been tested against the newest strain — Omicron. However, EngeneIC's scientists are now planning to send blood samples to South Africa, where Omicron was discovered, to determine how effective it will be. EngeneIC joint Chief Executive, Dr Himanshu Brahmbhatt, believes it will be effective. "These high-affinity antibodies are capable of locking on in such a way that it hangs on — no matter what mutant comes along," he said."

Small Sydney company strikes billion-dollar biotech deal for groundbreaking treatments https://www.9news.com.au/national/sydney-tech-company-strikes-biotech-deal-for-covid19-vaccine-and-cancer-treatment/58867647-97a5-4451-9975-91300ab487b5